NCT06528964 Proteinopathies Expression in Skin of Neurodegenerative Disorders
| NCT ID | NCT06528964 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidad Autonoma de San Luis Potosí |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-12-20 |
| Primary Completion | 2026-10-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2023-12-20 with a primary completion date of 2026-10-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 \[TDP43\]) in skin biopsies of patients with a neurodegenerative disease like Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus. The main question it aims to answer is: * Is there a specific pattern of aggregation of proteinopathies in skin biopsies in each neurodegenerative disease in comparison to healthy control subjects? Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence for detection of alpha-synuclein, amyloid-beta, phosphorylated tau and TAR DNA binding protein 43, and the aggregation patterns will be compared between patients with a neurodegenerative disease vs patient with normal pressure hydrocephalus vs healthy control subjects.
Eligibility Criteria
Inclusion Criteria for patients: * Patients 45 years and older * Men and women * Patients diagnosed with Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus * Patients that voluntarily accept to participate in the study and accept the consent form Inclusion Criteria healthy control subjects: * People 45 years and older * Men and women * Subjects can be related to a patient but not by blood (for example spouse of a patient) * Subjects don't have direct family history of a neurodegenerative control * Subjects don't have any clinical findings suggesting dementia * Subjects voluntarily accept to participate in the study and accept the consent form Exclusion Criteria: * Patients or controls that have a personal history of cerebrovascular disease, psychiatric disease, post traumatic dementia or HIV related dementia * Patients in which the diagnosis is not clear or hasn't been confirmed * Patients or controls that have a neuroinfection * Patients or controls that a diagnosed skin disease * Patients that have an "atypical" presentation of the disease * Patients or controls that have diagnosis of a coagulopathy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06528964 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06528964 currently recruiting?
Yes, NCT06528964 is actively recruiting participants. Contact the research team at ilrole@yahoo.com.mx for enrollment information.
Where is the NCT06528964 trial being conducted?
This trial is being conducted at San Luis Potosí City, Mexico.
Who is sponsoring the NCT06528964 clinical trial?
NCT06528964 is sponsored by Universidad Autonoma de San Luis Potosí. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.